The vote came from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee, which reviewed Capricor Therapeutics' application for the cell therapy. Advisory committee recommendations are advisory only. Families who want a community explanation of what follows an advisory committee meeting have a scheduled touchpoint. Standard Duchenne cardiac management, including the heart medications a cardiologist already prescribes, is unaffected by this vote. Duchenne advocacy organizations have scheduled a community town hall at 1 p.m. Eastern on what follows an advisory committee hearing.